Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 3, 2002

View Archived Issues

Drug pipeline for depression

LF-16-0687MS demonstrates efficacy in rat model of cerebral ischemia

Laquinimod, a potential therapeutic candidate for MS

GW-274150, a selective inhibitor of iNOS, attenuates collagen-induced arthritis in mice

Results of Zyrtec study in children with atopic dermatitis

Merck researchers identify novel subtype-selective NMDA NR2B antagonists

Asahi Glass patents new prostaglandin analogues with utility in glaucoma Rx

Antibacterial N-thiolated beta-lactams described in recent patent

Pfizer presents novel 5-HT7 partial agonists for depression, anxiety, etc.

Series of dual PDE7/PDE4 inhibitors covered by BMS patent

Inhibitors of tubulin polymerization prepared and tested at Aventis

New cathepsin inhibitors in early development at Medivir

Radiosensitizing effects of karenitecin in human glioma cells

Evidence that trimidox sensitizes malignant glioma cells to ionizing radiation

Metabolites of febrifugine with strong antimalarial activity in vitro and in vivo

New leads for antimalarial agents synthesized based on sponge-derived compounds

Phase I data demonstrate promising efficacy and safety for oral Raf kinase inhibitor

Efficacy of glatiramer in MS involves stimulation of BDNF production

INS-37217, a P2Y2 receptor agonist, enhances subretinal fluid reabsorption in preclinical models

Alinia approved for children with diarrhea caused by Cryptosporidium and Giardia

Novartis seeks approval of Zometa for tumor-induced hypercalcemia in Japan

Argenta Discovery and Lundbeck extend research agreement

Novartis initiates ZENSAA study of Zelmac in IBS

NICE updates diabetes treatment guidelines in U.K.

Dimethaid completes second installment payment of Oxo Chemie purchase

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...